Incyte
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT05219864
- Locations
- πΊπΈ
Raoof Md Encino, Encino, California, United States
πΊπΈSouthwest Skin Specialists Phoenix Biltmore, Phoenix, Arizona, United States
πΊπΈFirst Oc Dermatology, Fountain Valley, California, United States
Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 77
- Registration Number
- NCT05127421
- Locations
- πΊπΈ
Science37, Culver City, California, United States
A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 7
- Registration Number
- NCT05101369
- Locations
- π¬π§
Covance Leeds Cru, Leeds, United Kingdom
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT05099445
- Locations
- πΊπΈ
Inland Empire Liver Foundation, Rialto, California, United States
πΊπΈNucleus Network Minneapolis Clinic, Saint Paul, Minnesota, United States
πΊπΈClinical Pharmacology of Miami, Hialeah, Florida, United States
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
- Conditions
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT05090891
- Locations
- πΊπΈ
University of California San Francisco Medical Center, San Francisco, California, United States
πΊπΈMayo Clinic Rochester, Rochester, Minnesota, United States
πΊπΈChildren'S Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia
- Conditions
- Interventions
- First Posted Date
- 2021-10-11
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 13
- Registration Number
- NCT05073458
- Locations
- π΅π±
Investigative Site PL001, Legnica, Poland
π΅π±Investigative Site PL005, Opole, Poland
π¦πΉInvestigative Site AT002, Salzburg CET, Austria
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 146
- Registration Number
- NCT05061693
- Locations
- πΊπΈ
Investigative Site US016, Miami, Florida, United States
π΅π±Investigative Site PL004, Torun, Poland
πΊπΈInvestigative Site US010, Phoenix, Arizona, United States
Study of Ruxolitinib Cream in Children With Atopic Dermatitis
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 29
- Registration Number
- NCT05034822
- Locations
- πΊπΈ
Desert Sky Dermatology, Gilbert, Arizona, United States
πΊπΈOhio Pediatric Research Association, Dayton, Ohio, United States
πΊπΈAdvanced Medical Research Pc, Sandy Springs, Georgia, United States
Study of INCA 0186 in Subjects With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 57
- Registration Number
- NCT04989387
- Locations
- πΊπΈ
Emory University, Atlanta, Georgia, United States
π§πͺUniversitair Ziekenhuis Antwerpen (Uza), Edegem, Belgium
π³π±University Medical Center Groningen, Groningen, Netherlands
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT04981795
- Locations
- πΊπΈ
University of California, Irvine Medical Center, Orange, California, United States
πΊπΈAlabama Oncology, Birmingham, Alabama, United States
πΊπΈClearview Cancer Institute, Huntsville, Alabama, United States